EGFR and colorectal cancer: Globally our findings indicate that EGFR GCN as determined either by FISH or CISH may represent a valuable asset in the common effort of better defining, among the group of metastatic K-RAS colorectal cancer patients treated with anti-EGFR antibodies, those more likely to benefit from such a treatment strategy.